Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.67 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886505 | 0.96 | PARP1 (0.70) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL3883944 | 0.92 | PARP1 (0.57) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL61111 | 0.92 | PARP1 (0.58) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL60650 | 0.91 | PARP1 (0.57) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL60751 | 0.89 | PARP1 (0.53) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL3874952 | 0.89 | PARP1 (0.67) | PARP1TNKSTNKS2PARP2 | |
| 2X-121 SCHEMBL29393542 | 0.87 | PARP1 (0.66) | PARP1TNKSTNKS2PARP2 | |
| 2X-121 SCHEMBL31157849 | 0.87 | PARP1 (0.66) | PARP1TNKSTNKS2PARP2 | |
| 2X-121 SCHEMBL3886731 | 0.87 | PARP1 (0.66) | PARP1TNKSTNKS2PARP2 | |
| SCHEMBL3876635 | 0.87 | PARP1 (0.68) | PARP1TNKSTNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2842956-A1 | PARP inhibitor compounds, compositions and methods of use | Eisai Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8894989-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8894989-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MGI GP, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009046205-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI RESEARCH INSTITUTE (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | PARP1 1/4885TNKS 15/4885TNKS2 36/4885 |
| US-20090098084-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | PARP1 1/4885TNKS 15/4885TNKS2 36/4885 |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | PARP1 1/4885TNKS 17/4885TNKS2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.